Cloning, Expression And Immunogenicity Of Recombinant Bacille Calmette-Guerin (BCG) Containing T And B Cell Epitopes Of Mycobacterium Tuberculosis [QR82.M95 R737 2008 f rb]. by Mohamud, Rohimah
CLONING, EXPRESSION AND IMMUNOGENICITY 
OF RECOMBINANT BACILLE CALMETTE-GUERIN 
(BCG) CONTAINING T AND B CELL EPITOPES OF 
Mycobacterium tuberculosis 
 
 
 
 
 
 
 
 
 
 
ROHIMAH BINTI MOHAMUD 
 
 
 
 
 
 
 
 
 
 
 
UNIVERSITI SAINS MALAYSIA 
 
2008 
CLONING, EXPRESSION AND IMMUNOGENICITY 
OF RECOMBINANT BACILLE CALMETTE-
GUERIN (BCG) CONTAINING T AND B CELL 
EPITOPES OF Mycobacterium tuberculosis 
 
 
 
 
by 
 
 
 
ROHIMAH BINTI MOHAMUD 
 
 
 
 
Thesis submitted in fulfillment of the  
requirements for the degree  
of Master of Science  
 
 
 
 
 
 
 
 
UNIVERSITI SAINS MALAYSIA 
 
2008 
 ii
DEDICATIONS 
 
 
 
 
This thesis is specially dedicated to: 
 
My beloved husband, Mohd. Shamsul Hisham bin Mat Hassan Latfi 
My daughters, Fatin Shahirah, Fatin Shakirah and Alissa Shafiyah 
My parents, Mohamud bin Awg. Kechik and Siti Bidah binti Loman 
 
Thank you for your love, patience and encouragement. 
 
May Allah bless you all… 
 
 
 
 iii
ACKNOWLEDGEMENTS 
 
 
 
 
In the name of Allah, the Most Generous and the Most Merciful. All praise are 
due to Allah for His guidance and peace that give me the ingredients of success. 
 
I wish to acknowledge several people who have been involved directly or indirectly 
during this research project. 
 
 
Above all, I would like to thank my supervisor, Prof. Norazmi Mohd. Nor for his support, 
excellent guidance and supervision throughout the experimental work and also during 
the writing of this thesis. His guidance and encouragement are greatly appreciated. 
 
 
I would also like to express my gratitude to my co-supervisor, Dr. Rapeah Suppian for 
the encouragement, kind guidance and helpful discussions during this study.  
 
 
I would also like to thank Assoc. Prof. Dr. Nik Soriani Yaacob and Dr. Shaharum 
Shamsuddin for advice, guidance and overall comments. 
 
 
I would like to extend my thanks to my friends and colleagues in the laboratory 
especially, K. Maryam, Asma, Teo, Rafeezul, Zila, Kenny, Boonyin, Syam, K. Ayu, K. 
La, Fatma, Amir and Wong Vic Cern. Not to forget, my friends in ZFZ and SS group, 
Eza, Zura, Abdah, K. Su, K. Nurul, Aniek, Yuni, Tini, Bad, Azan, Kak Lin, Venu and 
Nida. Thank you for both your friendship and assistance during the course of this study. 
 
 
A special thanks to my parents, Mohamud and Siti Bidah, my brothers and sisters for 
their support and guidance during this work. Not to forget to my parents-in-law, Hj. Mat 
Hassan Latfi and Hjh. Rofiah, my brothers- and sister-in-law for their support and 
encouragement. Finally I wish to acknowledge the greatest support, love and 
encouragement from my beloved husband, Mohd. Shamsul Hisham for his love and 
 iv
patience; thanks for being there and encouraging me when needed. My appreciation 
also goes to my beloved daughters, Fatin Shahirah, Fatin Shakirah and Alissa 
Shafiyah; they always make me happy. 
 
There are many people that I would like to thank for contributing directly or indirectly to 
this study. I cannot mention you all so I hope you feel my gratitude. 
 
 v
TABLE OF CONTENTS 
 
ACKNOWLEDGEMENTS iii 
TABLE OF CONTENTS v 
LIST OF TABLES xi 
LIST OF FIGURES xii 
LIST OF ABBREVIATIONS xiv 
LIST OF APPENDICES xvi 
ABSTRACT xvii 
ABSTRAK xix 
 
CHAPTER ONE : INTRODUCTION 
 
 
1.1 Background 1 
1.2 History of TB 1 
1.3 Global incidence of TB 1 
1.4 M. tuberculosis 4 
1.5 Transmission of M. tuberculosis 6 
1.6 Pathogenesis of M. tuberculosis 6 
1.7 Overview of TB disease 8 
1.8 TB in Malaysia 8 
1.9 TB in children 9 
1.10 Symptoms of TB 10 
1.11 Diagnosis of TB 10 
 1.11.1 Chest radiograph 10 
 1.11.2 Sputum test 11 
 1.11.3 Mantoux tuberculin skin test (TST) 11 
 1.11.4 Nucleic acid amplification (NAA) test  11 
 1.11.5 Interferon-gamma (IFN-γ) assay 12 
1.12 Treatment of TB 12 
1.13 Immunity to TB 13 
 1.13.1 Innate immunity 13 
 1.13.2 Adaptive immunity 15 
             1.13.2.1 Humoral immune response 15 
             1.13.2.2  Cellular immune response 16 
1.14 Vaccination and memory T cells 18 
 vi
1.15 BCG 20 
 1.15.1 Efficacy and effectiveness of BCG 20 
1.16 Development of effective vaccines against TB 21 
 1.16.1 Live vaccines 23 
            1.16.1.1 Attenuated mycobacteria 23 
            1.16.1.2 Recombinant BCG (rBCG) 23 
 1.16.2 Non-live vaccines 23 
             1.16.2.1 Subunit vaccine 23 
             1.16.2.2  DNA vaccine 24 
  1.16.3 Prime boost vaccination 24 
1.17 Potential candidate antigens of M. tuberculosis 25 
 1.17.1 Mtb8.4 25 
 1.17.2 Ag85B 25 
 1.17.3 ESAT-6 26 
 1.17.4 CFP10 26 
 1.17.5 MTP40 26 
1.18 Justification, objective and research plan 27 
 
CHAPTER TWO: MATERIALS AND METHODS  
 
 
2.1 Materials 29 
 2.1.1 Mouse strain 29 
 2.1.2 Rabbit strain 29 
 2.1.3 E. coli strains 29 
 2.1.4 Chemicals and reagents 29 
 2.1.5 Sterilized, deionised distilled water 
2.1.6 Enzymes 
34 
34 
 2.1.7 Antibodies  
2.1.8 Peptides 
34 
34 
 2.1.9 Primers  
2.1.10 Oligonucleotides 
34 
34 
 2.1.11 Plasmids 34 
 2.1.12 Laboratory equipment 
2.1.13 Laboratory kits and consumables 
43 
43 
 2.1.14 Media 43 
              2.1.14.1  Luria-Bertani (LB) Broth 43 
              2.1.14.2  Luria-Bertani Agar (LA) 43 
 vii
              2.1.14.3   7H9 Broth 43 
              2.1.14.4    7H11 Agar 47 
              2.1.14.5   RPMI medium 47 
 2.1.15  Buffers and solutions 47 
              2.1.15.1   ABTS substrate for ELISA 47 
              2.1.15.2.  Ammonium chloride/potassium (ACK) lysis      
buffer (1 x) 
47 
              2.1.15.3   Ammonium persulfate (AP) solution (20 %) 48 
              2.1.15.4   Ampicillin stock solution (100 mg/ml) 48 
 2.1.15.5   Blocking buffer for ELISA 48 
 2.1.15.6   Blocking buffer (5 %) for Western blotting 48 
 2.1.15.7   CaCl2 solution (100 mM) 48 
 2.1.15.8   Coating buffer for ELISA 49 
 2.1.15.9   Con A solution (1 mg/ml) 49 
 2.1.15.10   Coomassie blue solution 49 
 2.1.15.11   Dialysis buffer 49 
 2.1.15.12   Destaining solution 49 
 2.1.15.13   Detection solution for Western blotting 50 
 2.1.15.14   DNA markers 50 
 2.1.15.15   Elution buffer (buffer D and buffer E) 50 
 2.1.15.16   Ethanol solution (70 %) 50 
 2.1.15.17   EtBr solution (10 mg/ml) 50 
 2.1.15.18   EDTA solution (0.5 M) 50 
 2.1.15.19   Glycerol solution (10 %) 51 
 2.1.15.20   Glycerol solution (80 %) 51 
 2.1.15.21   HEPES solution 51 
 2.1.15.22   HCl solution (1 M) 51 
 2.1.15.23   INH solution (10 mg/ml) 51 
 2.1.15.24   IPTG solution (1 M) 51 
 2.1.15.25   Loading dye solution 52 
 2.1.15.26   Kanamycin solution (50 mg/ml) 52 
 2.1.15.27   Lysis buffer 52 
 2.1.15.28   MgCl2 solution (100 mM) 52 
 2.1.15.29   [methyl-3H] Thymidine solution 52 
 2.1.15.30   NaOH solution (3 M) 53 
 2.1.15.31   Perm/ Wash Buffer (1 x) 53 
 viii
 2.1.15.32   PBS solutions 53 
 2.1.12.33   PMSF solution (100 mM) 53 
 2.1.12.34   Resolving buffer for SDS-PAGE 53 
 2.1.12.35   Running buffer for SDS-PAGE 54 
 2.1.12.36   Sample buffer for SDS-PAGE 54 
 2.1.12.37   Stacking buffer for SDS-PAGE 54 
 2.1.12.38   Staining buffer for flow cytometry 54 
 2.1.12.39   Stop solution for ELISA 54 
 2.1.12.40   Tris-acetate-EDTA (TAE) stock solution (50 x) 55 
 2.1.12.41   Tris-base solution (1.5 M) containing 0.4 % SDS  55 
 2.1.12.42   Tris-EDTA (TE) buffer 55 
 2.1.12.43   Tris-HCl solution (1.5 M) containing 0.4 % SDS 55 
 2.1.12.44   Trypan blue solution (0.4 %)  55 
 2.1.12.45   Towbin transfer buffer 55 
 2.1.12.46   Washing buffer (buffer C) 56 
2.2 Methods   56 
 2.2.1 Primers and oligonucleotides preparation 56 
 2.2.2 Synthetic peptide preparation 56 
 2.2.3 Preparation of Polymerase Chain Reaction (PCR) master mix 56 
 2.2.4 Preparation of E. coli competent cells 57 
 2.2.5 Transformation into E. coli competent cells 60 
 2.2.6 Preparation of BCG competent cell 60 
 2.2.7 Transformation of DNA into BCG competent cell 61 
 2.2.8 Determination of colony forming unit (CFU) of BCG/rBCG  
culture 
61 
 2.2.9 Glycerol stock of E. coli 61 
 2.2.10 Extraction of plasmid DNA 62 
 2.2.11 Quantification of DNA 63 
 2.2.12 DNA ligation 63 
 2.2.13 A-tailing protocol 63 
 2.2.14 TOPO® cloning reaction 63 
 2.2.15 PCR screening 66 
 2.2.16 DNA sequencing 66 
 2.2.17 Long term storage of DNA products 66 
 2.2.18 RE digestion 66 
 2.2.19 Agarose gel electrophoresis 66 
 ix
 2.2.20 DNA extraction from agarose gel 68 
 2.2.21 Protein analysis 69 
    2.2.21.1 Protein expression in E. coli 69 
          2.2.21.1.1 Optimization of incubation time for optimum  
expression  
69 
          2.2.21.1.2 Preparation of cleared E. coli lysates 69 
          2.2.21.1.3 Large scale protein production 70 
          2.2.21.1.4 Purification of 6x-His tagged protein 70 
          2.2.21.1.5 Protein sample preparation 71 
          2.2.21.1.6 Resolving and stacking gel preparation 71 
          2.2.21.1.7 SDS-PAGE 71 
          2.2.21.1.8 Western blotting 71 
          2.2.21.1.9 Immunoassay  73 
          2.2.21.1.10 Dialysis 74 
          2.2.21.1.11 Quantification of protein concentration 74 
     2.2.21.2 Protein expression in BCG 74 
 2.2.22 Polyclonal antibody production 75 
     2.2.22.1 Immunization of rabbit  75 
     2.2.22.2 Blood collection from rabbit 75 
 2.2.23 Immunogenicity study 77 
     2.2.23.1 Preparation of candidate vaccines and controls for 
immunization 
77 
     2.2.23.2 Immunization of mice 77 
     2.2.23.3 Blood collection from mice 77 
     2.2.23.4 Splenocytes preparation 79 
     2.2.23.5 Determination of cell concentration 79 
     2.2.23.6 Cell culture 80 
     2.2.23.7 LTT 80 
     2.2.23.8 Intracellular cytokine assay 81 
     2.2.23.9 Flow cytometry analysis 82 
     2.2.23.10 ELISA 82 
 2.2.24 Stability and safety study of rBCG 83 
 2.2.25 Statistical analysis 83 
 
 
 x
CHAPTER THREE: RESULTS 
 
 
3.1 Introduction 84 
3.2 Construction of recombinant plasmids 84 
3.3 Production of the polyclonal anti-Mtb8.4 antibody 94 
3.4 Construction and expression of rBCG 94 
3.5 Immunogenicity studies 94 
 3.5.1 LTT 94 
 3.5.1.1 LTT of rBCG018-immunized mice 94 
 3.5.1.2 LTT of rBCG032-immunized mice 102 
 3.5.2 Antibody response of mice immunized with rBCG 102 
 3.5.2.1 Total IgG of rBCG018- and rBCG032-immunized      
mice 
105 
 3.5.2.2  IgG subclasses of rBCG032-immunized mice 105 
 3.5.3 Detection of intracellular cytokines produced by CD4+ and 
CD8+ T cells 
105 
          3.5.3.1 Intracellular cytokines produced by CD4+ T cells 108 
          3.5.3.2 Intracellular cytokines produced by CD8+ T cells 108 
3.6 Preliminary safety and stability studies 110 
CHAPTER FOUR: DISCUSSION AND CONCLUSION 
118 
REFERENCES 
126 
LIST OF APPENDICES 
156 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 xi
LIST OF TABLES 
 
 
 
2.1 List of chemicals and reagents  
 
30 
2.2 List of enzymes 
 
35 
2.3 List of antibodies 
 
36 
2.4 List of synthetic peptides and antigen 
 
37 
2.5 List of primers 
 
38 
2.6 List of oligonucleotides used for assembly PCR 
 
39 
2.7 Map of plasmid vectors 
 
41 
2.8 List of equipment 
 
44 
2.9 List of kits and consumables 
 
45 
2.10  Composition of a 25 μl typical PCR master mix 
 
58 
2.11 Composition of 10 μl A-tailing PCR 
 
64 
2.12 Composition of 6 μl TOPO® cloning reaction 
 
65 
2.13 Composition of 20 μl RE digestion 
 
67 
2.14 Composition for SDS-PAGE preparation  
 
72 
3.1 The synthetic gene cloned into the pCR®-2.1 TOPO® 
cloning vector 
 
91 
3.2 CFU of rBCG after 2 weeks of incubation 
 
99 
3.3 Summary of the fold increase as compared to the  
BCG-immunized mice group (CD4+)  
 
109 
3.4 Summary of the fold increase as compared to the  
BCG-immunized mice group (CD8+)  
 
111 
 
 
 
 
 xii
LIST OF FIGURES 
 
 
1.1 TB notification rates in 2001  
 
3 
1.2 AFB smear  
 
5 
1.3 The chronology of events of M. tuberculosis infection 
 
7 
1.4 Vaccine induction of memory T cells in humans 
 
19 
1.5 Results of various controlled clinical trials of BCG vaccine 
 
22 
1.6 Flow chart of research strategy 
 
28 
2.1 Schematic outline of assembly PCR  
 
59 
2.2 Production of polyclonal antibody against Mtb8.4 
 
76 
2.3 Immunization of mice 
 
78 
3.1 Map and sequence of the T cell epitopes, designated as 
TBvac1.0 Fragment (399bp) 
 
85 
3.2 Map and sequence of the T cell epitopes, designated as 
TBvac2.0 Fragment (264bp) 
 
86 
3.3 Map and sequence of the B cell epitopes, designated as 
TBvac3.0 Fragment (282bp) 
 
87 
3.4 Agarose gel electrophoresis showing the product of assembly 
and amplification of TBvac1.0 Fragment 
 
88 
3.5 Agarose gel electrophoresis showing the product of assembly 
and amplification of TBvac2.0 Fragment 
 
89 
3.6 Agarose gel electrophoresis showing the product of amplification 
of TBvac3.0 Fragment 
 
90 
3.7 Construction of the expression vector, pNMN022 
 
92 
3.8 Optimization for protein expression 
 
93 
3.9 Preparation of lysate for protein expression 
 
95 
 xiii
3.10 SDS-PAGE analysis of purified polyhistidine-tagged TBvac2.0 
protein 
 
96 
3.11 Construction of the shuttle plasmid, pNMN018 containing 
TBvac1.0 Fragment and Myco ORI. 
 
97 
3.12 Construction of the shuttle plasmid, pNMN032 containing 
TBvac1.0 Fragment and Myco ORI. 
 
98 
3.13 Expression of TBvac1.0 Fragment in BCG
 
100 
3.14 Expression of TBvac3.0 Fragment in BCG
 
101 
3.15 Lymphocyte proliferative response of rBCG018-immunized mice 
 
103 
3.16 Lymphocyte proliferative response of rBCG032- immunized mice 
 
104 
3.17 Profile of antigen-specific total IgG response against T and B cell 
epitopes in Balb/c mice 
 
106 
3.18 Mean OD of IgG subclasses in mice 
 
107 
3.19 Weight of mice 6 weeks after the 2nd booster (n=5) 
 
112 
3.20 Weight of organs after 6 weeks following the 2nd booster (n=5) 
 
113 
3.21 CFU of rBCG in selected organs of mice 6 weeks after the 2nd 
booster (n=5) 
 
115 
3.22 PCR screening on randomly selected colonies obtained from 
selected organs of rBCG018-immunized mice 
 
116 
3.23 PCR screening on randomly selected colonies obtained from 
selected organs of rBCG032-immunized mice 
 
117 
 
 
 
 
 
 
 
 
 xiv
LIST OF ABREVIATIONS 
 
 
AIDS                Acquired immunodeficiency syndrome 
AFB  Acid fast bacillus 
Ag85  Antigen 85 
APCs  Antigen presenting cells 
B.C                   Before Century 
BCG  Bacille Calmette Guerin 
bp                    base pair 
CD                  Cluster of differentiation 
CFU  Colony forming unit 
CFP                Culture filtrate protein 
CTL  Cytotoxic T lymphocyte 
CPM                Count per minute 
ddH2O  Deionised distilled water 
DNA  Deoxyribonucleic acid 
ETH                 Ethambuthol 
γδ  Gamma delta 
HIV  Human Immunodeficiency Virus 
IFN  Interferon 
IFN-γR             IFN-γ Receptor 
IL  Interleukin 
i.m  Intramuscular 
INH                  Isoniazid 
i.p  Intraperitoneal 
kDa  Kilo Dalton 
KO                   Knock out 
LTT                  Lymphocytes transformation test 
MHC  Major histocompatibility complex 
MDR-TB Multi drug resistant-TB 
NAA                Nucleic acid amplification 
NK  Natural killer 
OD  Optical density 
ORF                Open reading frame 
PAS                 P-aminosalicylic acid 
PBMC  Peripheral blood mononuclear cell 
 xv
PCR  Polymerase chain reaction 
PPD  Purified protein derivative 
PZA                 Pyrazinamide 
rBCG  Recombinant bacilli Calmette Guerin 
RBC                Red blood cell 
RD  Region of difference 
RE  Restriction enzyme 
RIF                  Rifampin 
RT                   Room temperature 
SI  Stimulation index 
TCM                 T central memory 
TEM                           T effector memory 
Th  T helper 
TB  Tuberculosis 
TLR                 Toll like receptor 
TNF  Tumor necrosis factor 
TST                 Tuberculin skin test 
WHO  World Health Organization 
 
 xvi
LIST OF APPENDICES 
 
 
 
1.1 Appendix A  
Cloning of multiple Mycobacterium tuberculosis epitopes in 
Mycobacterium bovis bacille Calmette-Gúerin (BCG)  
 
156 
1.2 Appendix B 
Expression and Immunogenicity study of recombinant 
Mycobacterium bovis  Bacille Calmette-Gúerin (BCG) expressing 
tuberculosis epitopes in Balb/c mice 
 
157 
1.3 Appendix C 
A DNA-recombinant BCG prime-boost approach as a potential 
immunization strategy against tuberculosis 
 
158 
1.4 Appendix D 
Expression and Immunogenicity study of recombinant 
Mycobacterium bovis  Bacille Calmette-Gúerin (BCG) expressing 
T and B cell epitopes of Mycobacterium tuberculosis 
 
159 
 
 
 
 
 
 
 
 
 
 
 
 
 
 xvii
CLONING, EXPRESSION AND IMMUNOGENICITY OF RECOMBINANT BACILLE 
CALMETTE-GUERIN (BCG) CONTAINING T AND B CELL EPITOPES OF 
Mycobacterium tuberculosis 
ABSTRACT 
Tuberculosis (TB) remains one of the leading causes of morbidity and mortality in 
humans. The only TB vaccine currently available is an attenuated strain of 
Mycobacterium bovis, bacille Calmette–Guerin (BCG). However, the efficacy of BCG 
continues to be debated. The BCG protection against adult pulmonary TB ranged from 
0 to 80 % in randomized control trials. In addition, the rising rates of mulit-drug resistant 
M. tuberculosis have worsened the situation. Thus, an improved TB vaccine is urgently 
needed. Recombinant BCG (rBCG) is one of the most potential approaches in evoking 
the immune response against TB. In this study, two different types of rBCG were 
constructed: rBCG expressing T cell epitopes from M. tuberculosis Ag85B antigens and 
Mtb8.4 protein (rBCG018) or a combination of the antigens fused to B cell epitopes 
from ESAT-6, CFP10 and MTP40 proteins (rBCG032). Polyclonal anti-Mtb8.4 was 
successfully raised in rabbit and subsequently used for rBCG expression. 
Immunogenicity study of the vaccine constructs were used for immunization of Balb/c 
mice. Specific IgG response was obtained against the ESAT-6 and CFP10 in the sera 
of rBCG032-immunized mice. Splenocytes from these mice showed a high response 
against the Ag85B antigens and the Mtb8.4 protein, whereas splenocytes from 
rBCG018-immunized mice elicited a lower response against Ag85B epitopes and a 
high response against Mtb8.4 protein. Mice immunized with the rBCG strains produced 
a Th1 pattern of response against the T cell epitopes. Six weeks after the final 
immunization, the rBCG constructs were recovered from spleen, lung, liver and 
peritoneal washout. The presences of both constructs in the colonies grown from the 
organ were detected by PCR. In conclusion, the data obtained from this study 
demonstrates that T and B epitopes expressed in a single rBCG construct induced 
 xviii
appropriate humoral and cellular immune responses against immunogenic epitopes 
from M. tuberculosis.  
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PENGKLONAN, EKSPRESI DAN IMUNOGENISITI BACILLE CALMETTE-GUERIN 
(BCG) REKOMBINAN YANG MENGANDUNGI EPITOP SEL T DAN B 
Mycobacterium tuberculosis 
ABSTRAK 
 
Tuberkulosis (TB) merupakan salah satu penyakit yang menyebabkan banyak 
kematian kepada manusia. Terdapat hanya satu vaksin TB pada masa ini iaitu strain 
yang telah dilemahkan, Mycobacterium bovis bacille Calmette–Guèrin (BCG). 
Bagaimanapun, keberkesanan BCG masih hebat diperdebatkan. Daripada kajian yang 
dijalankan secara rawak, keberkesanan BCG terhadap penyakit TB pulmonari dalam 
kalangan orang dewasa didapati di antara 0 hingga 80 %. Tambahan pula, kadar 
kerintangan drug TB yang sentiasa meningkat merumitkan lagi masalah yang sedia 
ada. Oleh itu, vaksin yang lebih berkesan terhadap TB sangat diperlukan. BCG 
rekombinan (rBCG) merupakan salah satu langkah yang berpotensi untuk 
meningkatkan sistem keimunan terhadap TB. Di dalam kajian ini, dua jenis rBCG telah 
dihasilkan: rBCG yang mengkodkan epitop sel T daripada M. tuberculosis iaitu antigen 
Ag85B dan protein Mtb8.4 (rBCG018) atau kombinasi antigen-antigen tersebut dengan 
epitop sel B iaitu ESAT-6, CFP10 dan protein MTP40 (rBCG032). Anti-Mtb8.4 
poliklonal telah berjaya dihasilkan di dalam arnab dan seterusnya digunakan dalam 
expresi rBCG. Kajian keimunan terhadap konstrak vaksin ini telah dijalankan di dalam 
mencit Balb/c. Gerakbalas IgG yang spesifik dapat diperhatikan terhadap epitop ESAT-
6 dan CFP10 dalam sera mencit yang diimunisasi dengan vaksin rBCG032. Splenosit 
daripada kumpulan mencit ini juga menunjukkan gerakbalas yang tinggi terhadap 
epitop Ag85B dan protein Mtb8.4. Splenosit mencit yang diimunisasi dengan vaksin 
rBCG018 merangsang gerakbalas yang rendah terhadap epitop Ag85B, tetapi 
menunjukkan tindak balas yang tinggi terhadap protein Mtb8.4. Sel T CD4+ dan CD8+ 
daripada splenosit mencit yang diimunisasi dengan kedua-dua rBCG menghasilkan 
gerakbalas Th1 terhadap epitop sel T. Selepas dimunisasi selama 6 minggu, kehadiran 
 xx
rBCG yang terdapat di dalam limpa, paru-paru, hati dan basuhan peritoneum koloni 
organ telah dapat dikesan. Sebagai kesimpulan, data yang diperolehi daripada kajian 
ini menunjukkan bahawa rBCG yang mengkodkan sel T dan B telah berupaya 
meningkatkan gerakbalas humoral dan sel terhadap epitop-epitop M. tuberculosis yang 
immunogenik. 
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CHAPTER ONE 
INTRODUCTION  
 
1.1 Background 
Tuberculosis (TB) remains one of the leading causes of death worldwide 
(Frieden et al., 2003). More than one-third of the world's population have been infected 
with TB and new infections are occurring at a rate of one per second (WHO, 2006).  
 
1.2 History of TB 
TB has been present in humans since ancient times. Mycobacterium 
tuberculosis was first viewed in 1882 when Robert Koch discovered a special staining 
technique that allowed identifying the organism and announced the discovery of TB 
bacillus on 24th of March 1882 (Reviewed by Kanai, 1990). The Sanatorium era began 
after the discovery of the tubercle bacilli by Robert Koch (Reviewed by Bloom and 
Murray, 1992). In 1982, the first World TB Day was held by World’s Health 
Organization (WHO). Studies have provided evidence for the presence of M. 
tuberculosis complex in ancient skeletal and mummified materials (Crubezy et al., 
1998; Haas et al., 2000; Mays et al., 2001; Zink et al., 2001). The deoxyribonucleic acid 
(DNA) analysis of the tissue samples from Egyptian mummies [2125 Before Century 
(B.C)] has shown that an original M. tuberculosis complex was similar to the recent M. 
tuberculosis (Crubezy et al., 1998; Zink et al., 2003). Brosch et al. (2002) reported that 
M. africanum, M. microti and M. bovis strains diverged from the progenitor of M. 
tuberculosis.  
 
1.3 Global incidence of TB  
TB is a major health problem of worldwide concern both in developing as well 
as in industrialized countries. In 2002, almost 9 million new TB cases occurred (WHO, 
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2006). One out of 6 adults (15-59 years old) who live in developing countries dies from 
this disease (Murray et al., 1990; Dye et al., 1999)  and more than 8 million new cases 
of TB develop every year (Dye et al,. 1999). The number of deaths by TB (3 million 
people) is higher than the number of those caused by heart disease, cancer or any 
other infectious agents (Murray et al., 1992). Moreover, more than 90 % of all TB cases 
and deaths occur in developing countries (Bloom & Murray, 2003; WHO Fact Sheet, 
2003). The incidence of TB has increased significantly in areas with high rates of 
human immunodeficiency virus (HIV) infection, particularly in sub-Saharan Africa. WHO 
(WHO Fact Sheet, 2000) reported that the TB incidence rates in this area increased 
three-fold in the 1990s.  It is estimated that most people infected with HIV (90 %) are in 
developing countries, especially in the 20-35 age group. In some areas, 70 % of new 
TB patients are HIV co-infected (Elliot et al., 1990; De Cock et al., 1992). Worldwide, 
TB is the most common cause of death among acute immunodepression syndrome 
(AIDS) patients, killing 1 of every 3 of them.  
 
Besides co-infection with HIV, factors that are related to the high TB burden include 
homelessness and poverty, increasing number of refugees, reduction of governmental 
support in TB prevention and lack of treatment programs (Brudney & Dobkin, 1991). 
Another reason for the rising rate of TB cases is due to the high rate of immigration 
from countries with a high incidence of TB.  
 
TB is the leading infectious cause of death among people in more than 5 years of age 
in South-East Asia and accounts for approximately 33 % of all the cases of TB in the 
world. Within South-East Asia, more than 95 % of cases are found in India, Indonesia, 
Bangladesh, Thailand, and Myanmar (Murray et al., 1990; Kochi, 1991; Bloom and 
Murray, 1992). Frieden et al. (2003) reported that 80 % of new TB cases occur in 22 
high-burden countries (Figure 1.1).  
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      Figure 1.1: TB notification rates in 2001 (Adapted from Frieden et al., 2003). 
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1.4 M. tuberculosis  
Tubercle bacilli belongs to a distinctive genus of Mycobacterium, which include 
several closely related species of obligate aerobes whose growth is facilitated by 
carbon deoxide (CO2). All members of the Mycobacterium genus are Gram-positive 
bacteria. It has a complex cell wall structure that contains unique mycolic acid (Floyd et 
al., 1992). They are non-motile, non-spore forming, straight or slightly curved rod-
shaped microbes, 1-4 mm in length and between 0.3-0.6 mm in diameter (Figure 1.2) 
(Iseman, 2000). The genome of M. tuberculosis is 4,411,529 base pairs (bp) long with 
3,924 predicted protein-coding sequences.  
 
M. tuberculosis has a high content of guanine (G) and cytosine (C) in its DNA. 
The high GC content of 65.6 % may be one of the survival strategies employed by the 
bacteria, since stability of DNA increases directly with number of GC bonds (Cole et al., 
1998). M. tuberculosis contains granules and vacuoles and grows very slowly doubling 
its population every 18-24 hours. This characteristic causes delays in diagnosis by 
culture because the laboratory cultures of clinical materials must be incubated for 2 to 
12 weeks to obtain 103-104 bacteria. Another characteristic that helps M. tuberculosis to 
survive both in the body and in the exterior environment is the resistance to chemicals 
and drying. They are resistant to drying especially in sputum, where they can remain 
viable for 6-8 months. They are also resistant to 3 % hydrogen chloride (HCl), 6 % 
hydrogen sulfate (H2SO4) and to 4 % sodium hydroxide (NaOH). The cell wall structure 
of M. tuberculosis is different among prokaryotes and it is the major determinant of 
virulence. The cell wall contains peptidoglycan and lipid complex (lipids, glycollipids 
and polysacchatides) (Bloom, 1994). The success of M. tuberculosis as a pathogen 
relies on their ability to survive in the environment and to persist in the host for long 
periods of time.  
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1.5 Transmission of M. tuberculosis  
M. tuberculosis is carried by airborne particles when persons, who have 
pulmonary TB sneeze, cough, speak or sing. The particles stay for prolonged periods 
of time in the air. The infectious particles can also be created in other ways either 
during a procedure to irrigate a TB infected abscess, during laboratory processing of 
infected tissues or during an autopsy or embalming. Infection occurs when a 
susceptible person inhales particles containing M. tuberculosis. These particles 
traverse the mouth or nasal passages, upper respiratory tract and bronchi to reach the 
alveoli of the lungs. Once in the alveoli, the organisms are taken up by alveolar 
macrophages and spread throughout the body. This will either initiate to active disease 
or remain dormant and never cause disease (Schluger and Rom, 1998; Frieden et al., 
2003). 
  
1.6 Pathogenesis of M. tuberculosis 
Based on the study carried out by van Crevel et al. (2002), the chronology of 
events of TB infection starts with inhalation of M. tuberculosis (Figure 1.3). Following 
inhalation, dendritic cells and macrophages ingest the bacilli and destroy them by 
phagocytic process (Henderson et al., 1997; Thurnher et al., 1997).  
 
Alternatively, mycobacteria which escape the initial intracellular destruction will multiply 
and develop a primary complex consisting of a draining lymph node and this will lead to 
disruption of the macrophage. The disease may localize (primary TB) and 
hematogenous dissemination may occur after primary infection. Due to this 
dissemination, it will cause acute disease (milliary, meningitis TB). At this stage, the 
blood monocytes, inflammatory cells and dendritic cells are attracted to the lungs. Most 
often, infection is stabilized at this point and will activated months or years afterwards 
(post-primary TB or secondary infection). At this stage, the bacilli spread to other parts  
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Figure 1.3: The chronology of events of M. tuberculosis infection (Modified from van 
Crevel et al., 2002). 
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of the lungs and organs through the airways which patient will display some of the TB 
symptoms. In the final stages of TB infection, the organs involved may become 
damaged and if the patient is not given an appropriate treatment, the re-activation of 
TB can be fatal.  
 
1.7 Overview of TB disease  
TB can infect several organs of the human body such as brain, kidneys, bones 
and most commonly it affects the lungs which are known as pulmonary TB. It can be 
divided into two general states: latent TB infection and active TB (pulmonary or 
extrapulmonary). Extrapulmonary TB contributes for about 20 % of disease in non HIV-
infected people but more common in HIV-infected individuals (Shafer & Edlin, 1996). In 
extrapulmonary TB, the disease may spread to various sites around the body such as 
the lungs, including the meninges, pericardium, lymph nodes, bones and joints 
(including spine), genito-urinary tract (including kidneys), intestine, adrenal glands, skin 
and eyes. Lymph-node TB in the neck is called scrofula and Pott's disease for TB bone 
(especially the spine). In the spine, the most common location is the thoracic section. 
Iseman (2000) reported that involvement of the vertebral-body can be followed by 
disease of an adjacent invertebral disc. 
 
1.8 TB in Malaysia  
The state with the highest disease burden is Sabah (143.7 cases/ 100,000 
population) followed by Wilayah Persekutuan (121.7 cases/ 100,000 population), 
Sarawak (87.4 cases/ 100,000 population), Pulau Pinang (68.7 cases/ 100,000 
population) and Kelantan (55.5 cases/ 100,000 population). In terms of age-distribution 
of the cases, the majority of cases in Malaysia are in the 15-54 year age group with 
67.7 %, 29.5 % for more than 55 years age group and only 2.8 % cases for the 
childhood TB (Iyawoo, 2004). About 10 % of TB cases in Malaysia are discovered 
 9
among the immigrant population. The immigrants normally come from high TB burden 
neighbouring countries like Indonesia (45.9 %), Philippines (43.5 %), Bangladesh (3.6 
%), Myanmar (2.0 %) and Thailand (1.9 %) (Iyawoo, 2004).  The increasing number of 
TB cases in Malaysia is also contributed by the increasing number of HIV infection 
especially in drug addicts (Mohammad et al., 2002). The last factor is due to the lack of 
knowledge on cleanliness. TB control programme in Malaysia is performed by bacille 
Calmette-Guerin (BCG) immunization of all newborns and drug treatment of TB 
patients.  
 
1.9 TB in children  
The standard age categories by WHO for TB disease in children are those 
younger than 15 years old. WHO estimated that 1.3 million new cases of childhood TB 
occur each year and 450,000 children die due to the disease (WHO, 1989).  Dolin et al. 
(1994) reported that there was an estimated 7.5 million total TB cases, of which 
650,000 (9 %) occurred in children. Childhood TB appears to be increasing in many 
parts of the world (Nelson & Wells, 2004). In many industrialized countries, this 
situation is associated with new immigration patterns (Bibi et al., 1997; Nelson et al., 
2004). In many countries, this trend can be associated with many factors including poor 
economic situation and public health infrastructure, rising rates of HIV infection, 
difficulty of diagnosing childhood TB and the difficulty of diagnosing HIV-associated 
pulmonary infections in children. Several studies have reported that poverty, crowding 
and malnutrition are related with childhood TB (Qazi et al., 1998; van Rie et al., 1999). 
Some studies conducted in children have demonstrated that the rates of TB in children 
infected with HIV ranges from 1 to 19 % in areas with high prevalence of HIV infection  
(Lucas et al., 1996; Drut et al., 1997; Ikeogo et al., 1997; Chintu et al., 2002). 
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1.10 Symptoms of TB 
People with latent TB will have no symptoms because they are in inactive state 
of disease. However, people with TB disease may have any or all of the following 
symptoms; cough, feeling tired most of the time, loss of appetite and weight, fever and 
night sweats. As the illness progresses, people may cough up blood (hemoptysis) and 
develop severe breathing problems. The symptoms of extrapulmonary TB vary widely 
depending on which area of the body is infected. Thus, if TB affects the lymph nodes, it 
can cause swollen glands and a painless red mass, usually at the sides and base of 
the neck. In bone disease, the spine is typically involved and it usually causes back 
pain lasting weeks to months. Sometimes, the disease can progress to involve the 
spinal cord, causing paralysis. M. tuberculosis can also infect the joints, with slowly 
progressive swelling and pain, usually in a large joint such as the knee. 
 
1.11 Diagnosis of TB  
Fast and accurate diagnosis is a very important element of global health 
measurement to control any diseases. There are some diagnostic techniques that have 
been developed in order to detect TB.  
 
1.11.1 Chest radiograph  
The chest radiograph is an important tool in the diagnosis of pulmonary TB. 
Pulmonary TB typically demonstrates a number of abnormalities on chest radiographs. 
Primary pulmonary TB most commonly reveals hilar lymphadenopathy, which may 
cause right middle lobe compression and atelectasis (American Thoracic Society, 
2000a). Pulmonary infiltrates may be seen in primary TB, typically in the middle or 
lower lobes, but cavitary lesions are uncommon (American Thoracic Society, 2000a). 
Chest radiograph may be normal in patient with culture proven TB, especially in 
immunosuppressed patients (Marciniuk et al., 1999).  
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1.11.2 Sputum test 
The standard in TB diagnosis is clinical examination, combined with the direct 
microscopic examination of sputum and culture of bacteria. A patient suggestive of 
pulmonary TB should have the sputum test on mycobacterial strains by microscopic 
examination and cultures. Results of M. tuberculosis culture can be up to 8 weeks and 
in 10-20 % of cases the bacillus is not successfully cultured (Pottumarthy et al., 1999). 
If the patient has pulmonary TB by radiographs but no diagnostic sputum sample, then 
bronchoscopy should be considered to confirm the diagnosis.  
 
1.11.3 Mantoux Tuberculin Skin Test (TST) 
The Mantoux TST is the only preferred method of testing patients for latent TB 
infections. It has been used for the past 50 years to support diagnosis of TB (Huebner 
et al., 1993). An intradermal injection of 0.1 ml purified protein derivative (PPD), which 
contains 5 tuberculin units, is applied onto the forearm. The interpretation of the test is 
based on the diameter of induration and not the diameter of erythema. A reaction equal 
to 5 mm is considered positive in HIV-positive patients, 10 mm is considered positive in 
people from high-prevalence countries and injection drug abusers.  The healthy adults 
are considered positive if the diameter is equal to or greater than 15 mm (American 
Thoracic Society, 2000b). However, this test gives poor specificity due to the response 
produce by BCG vaccination and exposure to non-TB mycobacteria which are similar 
to the response induced by infection with M. tuberculosis (Anderson et al., 2000).  
 
1.11.4 Nucleic acid amplification (NAA) test  
NAA test is carried out to distinguish between M. tuberculosis and M. avium. 
Schluger (2001) recommended the use of nucleic acid amplification test to rapidly 
diagnose TB patients whose mycobacterial smear is positive.  
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1.11.5 Interferon-gamma (IFN-γ) assay 
 IFN-γ assay has been developed to replace the TST. They operate on a T-cell 
based approach as TB infection evokes a strong T helper 1 (Th1) type cell-mediated 
immune response (Munk et al., 1997). IFN- γ assay is currently not in widespread use 
since it is very expensive. The assay is based on PPD and region of difference-1 (RD-
1) specific antigens are able to discriminate between M. tuberculosis and M. avium 
intracellular complex infection (Streeton et al., 1998). Moreover, in-vivo and in-vitro 
experiments have shown that the IFN- γ based on the RD-1 specific antigens have 
higher sensitivity and specificity than PPD in diagnosis of TB infection (van Pinxteren et 
al., 2000b; Arend et al., 2001; Brock et al., 2001).  
 
1.12 Treatment of TB  
TB can be treated by chemotherapy and this approach has been started in the 
late 1940s with the introduction of streptomycin. The objective of this approach is to 
eradicate all tubercle bacteria from the patient and to prevent secondary resistant 
bacteria. Subsequently, several drugs were introduced including p-aminosalicylic acid 
(PAS) (1946), isoniazid (INH) (1952), cycloserine (1955), kanamycin (1957), rifampin 
(RIF) (1965), ethionamide (1966), ethambuthol (ETH) (1968) and pyrazinamide (PZA) 
(1970) (reviewed by Friedman, 2000). The modern short course chemotherapy consists 
of 2 months PZA, 6 months INH and RIF. ETH is added if multi drug resistant-TB 
(MDR-TB) is suspected (American Thoracic Society, 1993b). INH is important in 
inhibiting the synthesis of mycolic acid (Petrini and Hoffner, 1999). PZA plays an 
important role in the intensive phase of the bacteria (Mitchinson, 2005). RIF is an 
important agent in the treatment of TB and has bactericidal properties against both 
intracellular and extracellular M. tuberculosis (Friedman, 2000). ETH inhibits the 
synthesis of arabinogalactan and interrupts the mycobacterial cell wall synthesis 
(Mikusova et al., 1995). In the late 1970s, TB drug development stopped as it was 
 13
assumed that the effective drug and the combination with BCG vaccination 
programmes would lead to the prevention of TB as a public health threat. 
Unfortunately, more than two-thirds of TB patients do not receive an effective control of 
TB treatment in certain areas. Nachega & Chaisson (2003) reported that this 
phenomenon resulted in the MDR-TB defined as to M tuberculosis that is resistant to at 
least two drugs, INH and RIF. Therefore, an effective surveillance is very important in 
reducing the potential for MDR-TB, and this is one of the essential factors in gaining 
control of the global TB problem.  
 
1.13 Immunity to TB  
The human defense system consists of the innate and adaptive immune 
system. These immune systems synergize to activate and execute an immune 
response against the infection. The immune response to M. tuberculosis is complex 
and incompletely understood because M. tuberculosis is an intracellular pathogenic 
bacterium which has sophisticated mechanisms to survive inside host mononuclear 
phagocytic cells (Coler et al., 2001).  
 
1.13.1 Innate immunity  
Responses independent of lymphocytes have been termed natural immunity, 
innate immunity or T-independent responses (Bancroft et al., 1991; Fearon & Locksley, 
1996; Medzhitov & Janeway, 1998). Their responses to pathogens are fast and 
immediate, which has led to the concept that the innate response is the initial step in 
the host response to initiate early defense during the primary infection.  
 
The innate response includes the response of various leukocytes, in particular the cells 
of the mononuclear phagocyte system (the macrophage and dendritic cell), 
ganulocytes and natural killer (NK) cells. Phagocytic cells play a key role in the initiation 
and direction of adaptive T-cell immunity by presentation of mycobacterial antigens and 
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expression of co-stimulatory signals and cytokines. When M. tuberculosis first enters 
the alveolar macrophage, phagocytosis of M. tuberculosis becomes the first action 
taken as a response against this infectious agent. The cells involved in the 
phagocytosis process are dendritic cells, alveolar type II pneumocytes and monocyte-
derived macrophage (Bermudez & Goodman, 1996; Herdensen et al., 1997; Thurnher 
et al., 1997; van Crevel et al., 2002).  
 
Another crucial step in an effective host innate response is the recognition of M. 
tuberculosis or mycobacterial products on macrophage and dendritic cells by toll-like 
receptor (TLR) (Belvin & Anderson, 1996; Medzhitov et al., 1997; Visintin et al., 2001). 
TLR is an important connection between innate and adaptive immune defenses against 
microbial pathogens. The TLR family comprises of 11 members. The TLR11 has been 
discovered to be critical in the control of uropathogenic bacteria (Quesniaux et al., 
2004; Zhang et al., 2004). TLR2 is necessary for signaling of the mycobacterial 
lipoarabinomannan (LAM) (Means et al., 1999b; Underhill et al., 1999) and a 19 kDa M. 
tuberculosis lipoprotein (Brightbill et al., 1999; Noss et al., 2001). Its co-receptor, TLR6 
is able to control chronic TB infection (Nicolle et al., 2004). TLR4 may have a role in 
controlling TB infection and functions for the fine tuning of inflammation in chronic 
infections (Fremond et al., 2003). After the recognition of M. tuberculosis by TLRs, 
common signaling pathways lead to cell activation and production of cytokines which 
induces further activation.  
 
Host recognition of M. tuberculosis or mycobacterial products will lead to immune cell 
activation and production of specific cytokines. IFN-γ is the central cytokine and plays a 
key role in the Th1 development leading to host defense against M. tuberculosis 
infection (Belosevic et al., 1989; Sher & Coffman, 1992; Gately et al., 1998). The 
importance of IFN-γ was demonstrated by the increased susceptibility to 
mycobacterial infection of children with IFN-γ receptor (IFN-γR) deficiency (Jouanguy et 
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al., 1996 & 1997) and in IFN-γR knock out (KO) mice (Cooper et al., 1993; Flynn et al., 
1993). In humans, IFN-γ alone is insufficient to enhance the ability of macrophages to 
control the M. tuberculosis infection. Thus, other cytokines are important in working 
synergistically to decrease the infection caused by M. tuberculosis.  
 
Another cytokine is tumor necrosis factor-α (TNF-α) which is produced by the 
stimulation of T cells, macrophages and dendritic cells (Valone et al., 1988; Barnes et 
al., 1993; Henderson et al., 1997; Ladel et al., 1997; Serbina & Flynn, 1999). TNF-α 
plays a key role in granuloma formation. In TB patients, TNF-α is detected at the 
site of disease (Barnes et al., 1993; Law et al., 1996; Casarini et al., 1999). Interleukin 
(IL) -1β (IL-1 β) is expressed in excess (Schauf et al., 1993) and at the site of disease 
(Law et al., 1996; Bergeron et al., 1997). Studies in mice suggested that IL-1 β plays an 
important role in TB disease (Juffermans et al., 2000; Yamada et al., 2000). IL-12 is 
also one of the crucial cytokines in controlling M. tuberculosis infection and induced 
following phagocytosis of M. tuberculosis by macrophages (Henderson et al., 1997; 
Ladel et al., 1997). Lowrie et al. (1999) showed that administration of IL-12 DNA can 
reduce the bacterial numbers in mice with chronic M. tuberculosis infection. Besides IL-
12, IL-18 and IL-15 are also important in controlling M. tuberculosis infection. IL-15 
(Berg et al., 2002) and IL-18 (Berg et al., 2003) have been shown to increase the 
number of IFN-γ secreted by CD8+ T cells.   
 
1.13.2 Adaptive immunity  
1.13.2.1 Humoral immune response  
Humoral immune response is mediated by antibodies produced by activated B 
lymphocytes (plasma cells) and provides the most effective response against 
extracellular bacteria. These antibodies bind specifically to the antigens thereby 
eliciting the immune response. The immune system then neutralizes or eliminates them 
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from the body through ingestion and degradation of the antibody-antigen complex by 
phagocytes or by cell lysis (Abbas & Lichtman, 2001). During the primary infection of 
TB, IgM antibody response is activated to nonspecific polysaccharide antigens. The 
responses develop early but never reach high titer and are insufficient to eliminate the 
TB infection. Studies regarding humoral response in TB were focused on the 
development of diagnostic assays (Alifano et al., 1997; Laal et al., 1997). Demkow et 
al. (2002) developed an IgG assay against the 38 kDa and 16 kDa of M. tuberculosis 
recombinant mycobacterial antigens for the diagnosis of bone and joint TB.  
 
1.13.2.2 Cellular immune response 
Cell-mediated immune response is an important response to control M. 
tuberculosis infection. This response provides a major protective immune response to 
M. tuberculosis rather than the humoral responses (Kaufmann, 1995; Feng et al., 
1999). CD4+ T lymphocytes are central to the human immune response to M. 
tuberculosis infection (Boom, 1996), but supported by other T cell subsets such as 
CD8+ cytolytic T lymphocytes (CTL) and unconventional T cells (γδ and CD1+ T cells) 
(Boom, 1996).  
 
CD4+ T cells recognize antigens in the context of the major histocompatibility complex 
(MHC) class II molecules, whereas, CD8+ recognizes antigens presented by MHC class 
I molecules. In general, CD4+ is responsible for directing an immune response by 
activating effector cells, whereas CD8+ is the killer cells that lyse the infected cells by 
producing various cytokines such as IFN-γ and TNF-α (Schluger & Rom, 1998). 
Together, these two types of effector T lymphocytes play a critical role in controlling 
microbial infections. Several studies reported that CD4+, CD8+ and γδ T cells are all 
considered to play a crucial role in controlling TB infection in cattle (Cassidy et al., 
2001; Walravens et al., 2002; Vesosky et al., 2004).  
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Activated CD4+ T cells can differentiate into either Th1 or Th2 cells that secrete specific 
cytokines. In general, Th1 cells secrete IFN-γ and TNF-α, whereas Th2 cells secrete IL-
4, IL-5, IL-10 and IL-13. Th1 response is associated with a strong cell-mediated CD8+ T 
cell response whereas Th2 response is characterized by a humoral or antibody-
mediated immune response (Lucey et al., 1996). The activation of Th1 cells by M. 
tuberculosis antigens result in cytokine production, mainly IL-2 and IFN-γ. These 
cytokines will activate macrophages and other T cells (CD8+ and γδ T-cell) to provide 
strong protection against bacterial infection (Grange et al., 1995; Feng et al., 1999; 
Flynn & Chan, 2001; Raupach & Kaufmann, 2001).  
 
In general, CD8+ T cell uses two major mechanisms of lysis in order to provide 
protection against M. tuberculosis. CD8+ expresses perforin and granzymes to lyse the 
infected cells. In humans, CD8+ T cell produces granulysin that is toxic to M. 
tuberculosis and lyse the infected cells (Stenger et al., 1997 & 1998). Another 
mechanism to lyse the target cells is through the Fas/FasL pathway (Clark et al., 1995). 
In addition to killing an infected cell, CD8+ T cells mediate anti-microbial effector 
functions by secreting anti-microbial and cytokines such as IFN-γ and TNF-α (Herbein, 
1997).  
 
γδ and CD1+ T cells also produce IFN-γ which activate anti-mycobacterial activities in 
macrophages and effect the mycobacterial growth (Raupach & Kaufmann, 2001). This 
activation is supported by TNF-α. Tsukaguchi et al. (1995) demonstrated that γδ T cells 
have the capacity to display cytotoxicity and produce IFN-γ in response to M. 
tuberculosis infected macrophages. A study performed by D’Souza et al. (1997) 
reported that γδ T cells contribute in the early stages of disease. As the disease 
become chronic, apoptosis mediated by Fas/FasL clears the majority of M. tuberculosis 
reactive γδ T cells (Li et al., 1998). Raja (2004) suggested that γδ T cell is important in 
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patients with latent infection. Studies performed in a primate model demonstrated that 
the number and activity of γδ T cells increased during the primary mycobacterial 
infection and after BCG vaccination (Barnes et al., 1992).  
 
The CD1 family (group I CD1 molecules: CD1a, CD1b, CD1c and group II CD1 
molecule; CD1d) is the least common T cell subset in human peripheral blood and 
lung. CD1 seems to play a significant role in immune responses to infectious diseases 
such as TB and some types of uncontrolled cell growth (Brigl et al., 2004). In humans, 
CD1a, b, and c have been associated with effective immune response to leprosy and 
mycobacterial infections. Brigl et al. (2004) also showed that CD1 presentations are 
being downregulated following exposure to live M. tuberculosis.  
 
1.14 Vaccination and memory T cells  
TB infection and vaccination usually induce memory T cell. After vaccination, 
dendritic cells take up the microbial antigens and carry them to adjacent lymph nodes. 
In the lymph nodes, antigen-presenting dendritic cells that have migrated from the 
peripheral sites of infection will activate naïve T cells to differentiate into primary 
effector T cells (Figure 1.4) (Esser et al., 2003). During the activation phase, effector T 
cells can expand to more than 1000-fold within a few days (Goldrath & Bevan, 1999). 
These memory T cells express effector proteins such as perforin (Opferman et al., 
1999), granzyme B (Jacob & Baltimore, 1999) and cytokines (Saparov et al., 1999). 
After the activation stage, more than 90 % of the effector T cells die via apoptosis (Lin 
et al., 2000). This phenomenon is important in order to maintain the homeostasis and 
prevent autoimmunity (Lenardo et al., 1999). A few effector T cells become long-lasting 
‘memory’ T cells which retained their antigen specificity and can persist for a lifetime in 
the absence of antigen and even MHC molecules (Zinkernagel, 2000; Sprent & Surh, 
2001).  
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Figure 1.4: Vaccine induction of memory T cells in humans. (Modified from Esser et al., 
2003).  
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‘Memory’ in the T-cell compartment results from the presence of memory T cells, which 
are found at high frequencies and can respond faster and more efficiently than naïve T  
cells (Kedl & Mescher, 1998; Bachmann et al., 1999; Cho et al., 1999; Zimmermann et 
al., 1999). Memory T cells can be divided into the central memory (TCM – derived from 
lymph node) and effector memory (TEM – derived from peripheral tissues) subsets 
which can proliferate in response to an antigen or cytokines and perform effector 
functions (Sallusto et al., 2004). TCM are involved in secondary responses and long 
term protection whereas TEM are involved in immediate protection.  
 
 1.15 BCG 
BCG was developed by Albert Calmette and Camille Guerin at the Institute 
Pasteur in Lille, France between 1908 and 1920 from a virulent M. bovis strain via 231 
serial passages. Studies have shown that during in vitro passage, M. bovis became 
attenuated due to loss or rearrangement of several gene complexes (Mahairas et al., 
1996; Behr et al., 1999; Gordon et al., 1999; Brosch et al., 2001). BCG is the oldest 
vaccine currently used throughout the world over the century (Starke, 1991; Huebner, 
1996). It is believed that more than 3 billion doses of the vaccine have been 
administered worldwide (Fine, 1989). Vaccination with BCG still remains the standard 
for TB prevention in most countries because of its efficacy in preventing TB meningitis.  
 
1.15.1 Efficacy and effectiveness of BCG 
BCG is inexpensive, requires only one encounter with the baby and has minor 
side effects. Besides its wide usage as a vaccine against TB, BCG is also used as 
immunotherapy against intravesicular bladder cancer (Alexandroff et al., 1999). BCG is 
also a promising vehicle for delivery of heterologous antigens (Kaufmann & Andersen, 
1998). Such BCG-based carrier strains have been evaluated for the immunization 
against viral (Leung et al., 2000), bacterial (Abomoelak et al., 1999; Hayward et al., 
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1999) and parasitic pathogens (Matsumoto et al., 1998; Streit et al., 2000) as well as in 
anti-tumor vaccination models (Duda et al., 1995).  
 
However, its efficacy varies widely from 0 to 80 % in different populations. The low 
efficacy is consistent in many tropical regions of the world where the vaccine is most 
needed (Figure 1.5) (Fine, 1989; 1995). Lagranderie et al. (1996) reported that the 
differences of BCG strains, incorrect preparation of the freeze-dried vaccine, the age at 
vaccination and the methodological differences are important factors that contribute to 
the variable efficacy of the vaccine. However, the main reason for the failure of BCG is 
due to the exposure to non-TB mycobacteria which can block the multiplication of BCG. 
Brandt et al. (2002) reported that this exposure can prevent the induction of an efficient 
BCG-mediated immune response and give less protection against TB. The study also 
concluded that BCG is sensitive to the influence of preexisting immune responses to 
antigens shared with certain environmental strains. The efficacy of BCG vaccination 
also appears to vary with geographical latitude. The farther from the equator; the 
efficacy of the vaccine is higher (Brandt et al., 2002). Norazmi et al. (2005) reported 
that the failure of BCG may be due to the absence of important T cell antigens in BCG 
which are important in evoking the immune system against M. tuberculosis. 
 
1.16 Development of effective vaccines against TB 
The development of more effective TB vaccines include pre-infection vaccines 
to prevent primary infection, post-infection vaccines that inhibit TB progression in 
recently exposed individuals and therapeutic vaccines for MDR-TB patients (Ginsberg, 
2002). Moreover, a vaccine against latent TB infection is urgently needed to cure the 2 
billion individuals who are already infected (Dye, 2004). In order to generate an 
effective vaccine, some approaches have been developed including living and non- 
living putative TB vaccines that are better than the parent vaccine (Orme, 1999; 
McMurray, 2000; Andersen et al., 2001). 
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Figure 1.5: Results of various controlled clinical trials of BCG vaccine (Adapted from 
Orme, 1999).  
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1.16.1 Live vaccines 
1.16.1.1 Attenuated mycobacteria 
Attenuation aims to minimize the virulence of a pathogen. The attenuated 
mycobacteria can elicit protective immune responses, but does not cause any clinical 
disease. A number of M. tuberculosis, M. bovis and M. bovis BCG auxotrophs have 
been constructed with mutation in certain metabolic pathways (Guilera et al., 1996; 
Berthet et al., 1998a; Jackson et al., 1999). Mutant strains of M. tuberculosis have 
been constructed with mutations in antigen 85A (Ag85A) and Ag85B. These mutants 
showed slower growth rate within human and murine monocyte cell lines (Armitige et 
al., 2000). These efforts may lead to the generation of a more effective vaccine and to 
a better understanding of the biology of mycobacterial infection.  
 
1.16.1.2 Recombinant BCG (rBCG) 
rBCG techniques may be useful for the development of a more effective TB 
vaccine than the parental BCG strain (Ohara et al., 2001). The rBCG has been 
suggested to protect against TB meningitis (Colditz et al., 1994) and also able to 
minimize the dissemination of the bacteria from the primary lesion to other parts of the 
lungs (Orme, 1999). Recent studies carried out by Kawahara in 2006 indicated that 
their constructed rBCG-SIVGag has the ability to effectively induce long-lasting, cell-
mediated and humoral immunity against both viral and bacterial antigens in guinea 
pigs. These results suggest that rBCG-Gag has the potential to elicit specific immunity 
not only for TB but also for HIV.  
 
1.16.2 Non-live vaccines  
1.16. 2.1 Subunit vaccine  
A number of subunit vaccines which are based on various secreted and non-
secreted protein (lipid or carbohydrate) components of M. tuberculosis have been 
studied (Andersen, 1994; Horwitz et al., 1995; Roberts et al., 1995). Brandt and 
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colleagues (2002) suggested that the subunit vaccine may be much less influenced by 
prior contact with environmental mycobacteria and therefore more protective in 
preventing the disease. However, these non-living subunit vaccines still failed to 
provide better protection than BCG. Furthermore, the main disadvantage of subunit 
vaccines is that they are expensive to produce and require multiple boosters.  
 
1.16.2.2 DNA vaccine 
Another approach is the use of DNA vaccine encoding mycobacteria proteins 
incorporated into the plasmid. The plasmid contains a mammalian promoter that is 
injected into the muscle. Many researches have focused on the secreted antigens and 
heat-shock proteins (hsp) encoded in the DNA (Huygen et al., 1996; Tascon et al., 
1996; Baldwin et al., 1998; Lowrie et al., 1999). Vaccination with DNA encoding Ag85A 
(Huygen et al., 1996; Baldwin et al., 1998) and the 6-kDa early secretory antigenic 
target (ESAT-6) (Brandt et al., 1996; Kamath et al., 1999; Brandt et al., 2000) have 
been shown to induce significant protection against TB.  
 
1.16.3 Prime boost vaccination 
The prime-boost approach is based on the concept of administration of the 
same mycobacterial antigen in order to gain a higher level of immune response. This 
approach involves two approaches; homologous and heterologous boosting. 
Homologous boosting refers to the antigens being delivered by the same delivery 
system with each subsequent dose (McShane et al., 2001; 2004; McShane & Hill, 
2005). Heterologous boosting refers to the administration of the same mycobacteria 
antigens delivered by different vectors (McShane & Hill, 2005). It has been suggested 
that a combination of rBCG and DNA vaccines expressing various epitopes of M. 
tuberculosis administered in a prime-boost manner could be one of the best 
approaches to control TB infection (Norazmi & Musa, 2004; McShane & Hill, 2005) 
